The FDA has approved Cayston (aztreonam for inhalation solution, from Gilead Sciences) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa. Cayston is administered via the Altera Nebulizer System that allows patients to take the medicine in less than five minutes. The safety and efficacy of Cayston have not been established in pediatric patients <7 years of age, patients with forced expiratory volume in one second (FEV1) of <25% or >75% predicted, or patients colonized with Burkholderia cepacia.
Cayston is expected to be available by the end of next week through specialty pharmacies.
For more information call (877) 7CAYSTON or visit www.cayston.com.